Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 7/20 | 0.49 |
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | CLK1 | P49759 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30248371 | 0.88 | L3MBTL1 (0.57) | L3MBTL1LMNAMAPK1NPC1RAB9A | |
| SCHEMBL27311609 | 0.88 | L3MBTL1 (0.57) | L3MBTL1LMNAMAPK1NPC1RAB9A | |
| SCHEMBL30248235 | 0.88 | L3MBTL1 (0.57) | L3MBTL1LMNAMAPK1NPC1RAB9A | |
| SCHEMBL30247993 | 0.86 | L3MBTL1 (0.55) | L3MBTL1LMNAMAPK1NPC1RAB9A | |
| SCHEMBL27311841 | 0.85 | L3MBTL1 (0.53) | L3MBTL1LMNAMAPK1NPC1RAB9A | |
| SCHEMBL4396712 | 0.84 | MAOA (0.64) | L3MBTL1LMNAMAPK1NPC1RAB9A | |
| SCHEMBL31420249 | 0.83 | NPC1 (0.52) | L3MBTL1LMNAMAPK1NPC1RAB9A | |
| SCHEMBL31420245 | 0.82 | DYRK1A (0.51) | L3MBTL1LMNAMAPK1NPC1RAB9A | |
| SCHEMBL31420246 | 0.82 | DYRK1A (0.51) | L3MBTL1LMNAMAPK1NPC1RAB9A | |
| SCHEMBL31420252 | 0.82 | L3MBTL1 (0.51) | L3MBTL1LMNAMAPK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335427-A1 | SMALL MOLECULE INHIBITION OF DEUBIQUITINATING ENZYME JOSEPHIN DOMAIN CONTAINING 1 (JOSD1) AS A TARGETED THERAPY FOR LEUKEMIAS WITH MUTANT JANUS KINASE 2 (JAK2) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-10-10 | — | — | US | disclosed |
| EP-4377299-A1 | SMALL MOLECULE INHIBITION OF DEUBIQUITINATING ENZYME JOSEPHIN DOMAIN CONTAINING 1 (JOSD1) AS A TARGETED THERAPY FOR LEUKEMIAS WITH MUTANT JANUS KINASE 2 (JAK2) | Dana-Farber Cancer Institute, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023009982-A1 | SMALL MOLECULE INHIBITION OF DEUBIQUITINATING ENZYME JOSEPHIN DOMAIN CONTAINING 1 (JOSD1) AS A TARGETED THERAPY FOR LEUKEMIAS WITH MUTANT JANUS KINASE 2 (JAK2) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335427-A1 | SMALL MOLECULE INHIBITION OF DEUBIQUITINATING ENZYME JOSEPHIN DOMAIN CONTAINING 1 (JOSD1) AS A TARGETED THERAPY FOR LEUKEMIAS WITH MUTANT JANUS KINASE 2 (JAK2) | JAK1, JAK2, UBQLN1 | L3MBTL1 506/4885LMNA 4253/4885MAPK1 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.